In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes
Top Cited Papers
Open Access
- 1 May 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (5) , 1581-1582
- https://doi.org/10.1128/aac.46.5.1581-1582.2002
Abstract
In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.Keywords
This publication has 18 references indexed in Scilit:
- Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosisAntimicrobial Agents and Chemotherapy, 1997
- In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus sppAntimicrobial Agents and Chemotherapy, 1997
- Emerging Fungal Pathogens in Immunocompromised Patients: Classification, Diagnosis, and ManagementClinical Infectious Diseases, 1993
- Medical mycologyRevista do Instituto de Medicina Tropical de São Paulo, 1992
- FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1985
- An amphotericin B-resistant case of rhinocerebral mucor mycosisInfection, 1985
- Cardiac fungal infections: Review of autopsy findings in 60 patientsHuman Pathology, 1984
- Fungal Burn Wound InfectionJAMA, 1971
- Fatal Opportunistic Fungus DiseaseJAMA, 1967
- Transaminase levels in the postconvalescent phase of infectious hepatitisPublished by American Medical Association (AMA) ,1967